Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction and it is tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat (JNJ-54861911) has the potential for Alzheimer's Disease treatment[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,430.00 | |
50 mg | 8-10 weeks | $ 1,860.00 | |
100 mg | 8-10 weeks | $ 2,890.00 | |
1 mL * 10 mM (in DMSO) | 8-10 weeks | $ 456.00 |
Description | Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction and it is tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat (JNJ-54861911) has the potential for Alzheimer's Disease treatment[1]. |
Synonyms | JNJ-54861911 |
Molecular Weight | 367.4 |
Formula | C18H14FN5OS |
CAS No. | 1200493-78-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (680.46 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Atabecestat 1200493-78-2 Neuroscience BACE JNJ 54861911 JNJ54861911 JNJ-54861911 inhibitor inhibit